Mjames Lenhard, MD
Endocrinology, Diabetes & Metabolism · Burlington, MANPI 1245218148
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,685 of the $49,200 with a category attached, or 80.7%. 16 manufacturers reported payments, led by Bayer at 46.5% of the total. Reporting peaked in 2020 at $12,459 and has fallen 93.9% since, to $761 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $473.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$23K
- Johnson & Johnson$15K
- Lilly USA, LLC$7K
- Sanofi-aventis U.S. LLC$3K
- AstraZeneca$274
- Novo Nordisk$99
- plus $485 from 10 others
Across 7 payments — averaging $4777.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$32K
- AstraZeneca$1K
What the payments were for
- Consulting fees$5,25011%
- Speaking & faculty fees$39,68581%
- Travel & lodging$1,4073%
- Food & beverage$2,7876%
- Education$120%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 24 | $22,879 |
| Johnson & Johnson | 14 | $15,340 |
| Lilly USA, LLC | 28 | $6,793 |
| Sanofi-aventis U.S. LLC | 10 | $3,330 |
| AstraZeneca | 3 | $274 |
| Novo Nordisk | 5 | $99 |
| Tandem Diabetes Care, Inc. | 3 | $94 |
| Mannkind Corporation | 2 | $79 |
| Abbott | 3 | $64 |
| Merck | 2 | $54 |
| Medtronic(2 entities) | 3 | $47 |
| Amgen(2 entities) | 2 | $47 |
| Shire North American Group Inc | 2 | $45 |
| Boehringer Ingelheim | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,200 in reported general payments places this provider in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 290 | $505,729 |
| JardianceEmpagliflozin | 200 | $250,396 |
| TrulicityDulaglutide | 139 | $246,865 |
| FarxigaDapagliflozin Propanediol | 176 | $238,744 |
| MounjaroTirzepatide | 120 | $205,100 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 50 | $126,313 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 75 | $104,433 |
| Teriparatide | 33 | $99,679 |
| Tresiba Flextouch U-100Insulin Degludec | 105 | $86,194 |
| InvokanaCanagliflozin | 57 | $85,820 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 126 | $66,348 |
| JanuviaSitagliptin Phosphate | 59 | $64,285 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 25 | $45,589 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 232 | $30,577 |
| KerendiaFinerenone | 20 | $28,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $99 | $537,325335 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $6,793 | $465,272297 claims |
| Boehringer IngelheimJardiance | $23 | $250,396200 claims |
| AstraZenecaFarxiga | $274 | $238,744176 claims |
| Johnson & JohnsonInvokana | $15,340 | $85,82057 claims |
| MerckJanuvia | $54 | $64,28559 claims |
| BayerKerendia | $22,879 | $28,52820 claims |
| Sanofi-aventis U.S. LLCLantus | $3,330 | $5,12528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Burlington
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.